Large holder notice
Open the filing on sec.gov
Lexeo Therapeutics, Inc. (LXEO)
Nasdaq: LXEO · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2022
The companyfiscal 2022, as filed
Revenue$654,000
Net income-$59.3M
Earnings per share$-36.36
Operating cash flow-$54.6M
Cash$77.3M-43.1%
Debtn/a
Shareholders’ equity-$113M-103.1%
Shares, diluted1,630,348
Return on equity-40.5%
The recordfrom its filings
Filings in 202687
Newest filingNov 10 · SCHEDULE 13G
Annual reportMar 30, 2026
Quarterly reportAug 12, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$1.0M
Insider buys, 12 months$0.00
Patents granted0
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$87.3MCash from operations -$88.4Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Registration effective
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.